All In Biotech

Drug Trial Radar · NCT01853072

Nepafenac Once Daily for Macular Edema - Study 1

Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery

Last checked: Nov 20, 2026Latest source record: Aug 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 881 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

881

Actual

Start

Jun 2013

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
May 14, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.

Conditions

  • Non-Proliferative Diabetic Retinopathy
  • Cataract

Interventions

  • Nepafenac Ophthalmic Suspension, 0.3%Drug

    Test intervention

  • Nepafenac vehicleOther

    Inactive ingredients used as placebo comparator

  • Prednisolone acetateDrug

    1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90Time frame: Baseline to Day 14, and maintained through Day 90
  2. Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0)Time frame: Day 0 to Day 90

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.